10-Q: Coherus BioSciences Reports Q3 2024 Results, Faces UDENYCA Supply Interruption

Coherus BioSciences reports a net income of $79.2 million for the nine months ended September 30, 2024, driven by gains from asset sales, but faces a temporary supply interruption for UDENYCA.

Summary

• Coherus BioSciences reported a net income of $79.2 million for the nine months ended September 30, 2024, a significant turnaround from a net loss of $158.2 million in the same period last year.
• This positive result was primarily driven by gains from the sale of the CIMERLI and YUSIMRY franchises, which generated a net gain of $176.6 million.
• Net revenue for the nine months ended September 30, 2024 was $212.8 million, compared to $165.7 million for the same period in 2023.
• UDENYCA sales increased to $159.7 million for the nine months ended September 30, 2024, up from $90.9 million in the same period last year, driven by new presentations and increased market share.
• The company experienced a temporary supply interruption for UDENYCA due to production delays at a third-party packaging and labeling CMO.
• Coherus expects UDENYCA production to resume in early November 2024, with a significant number of units projected to be completed by the end of 2024.
• An additional packaging and labeling CMO is expected to start commercial supply of UDENYCA in the first quarter of 2025.
• The company repaid all outstanding indebtedness under its 2027 Term Loans, resulting in a $12.6 million loss on debt extinguishment.
• A new $38.7 million term loan facility was entered into in May 2024, along with a revenue participation agreement for $37.5 million.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company achieved a net income and increased UDENYCA sales, the temporary supply interruption and the loss on debt extinguishment temper the positive results. The future outlook is uncertain due to the supply issues.

Positives

• The company achieved a net income of $79.2 million for the nine months ended September 30, 2024, a significant improvement from a net loss of $158.2 million in the same period last year.
• UDENYCA sales increased to $159.7 million for the nine months ended September 30, 2024, up from $90.9 million in the same period last year.
• The company has diversified its labeling and packaging resources with an additional CMO expected to start commercial supply in the first quarter of 2025.
• The company repaid all outstanding indebtedness under its 2027 Term Loans.
• The company entered into a new $38.7 million term loan facility and a revenue participation agreement for $37.5 million.

Negatives

• The company experienced a temporary supply interruption for UDENYCA due to production delays at a third-party packaging and labeling CMO.
• The company expects net revenue in the fourth quarter of 2024 to be significantly less than the third quarter of 2024 due to the UDENYCA supply interruption.
• The company recorded a $12.6 million loss on debt extinguishment related to the payoff of the 2027 Term Loans.

Risks

• The company faces risks related to the temporary UDENYCA supply interruption and the timing of its resolution.
• The company relies on third-party manufacturers and CMOs, which exposes it to supply chain risks.
• The company faces competition in the biosimilar and immuno-oncology markets.
• The company's future financial performance depends on the success of its product candidates and its ability to obtain regulatory approvals.
• The company is subject to various legal and regulatory risks, including those related to healthcare laws and data privacy.
• The company's stock price may be volatile and subject to market fluctuations.

Future Outlook

The company expects net revenue in the fourth quarter of 2024 to be significantly less than the third quarter of 2024 due to the UDENYCA supply interruption. The company expects UDENYCA production to resume in early November 2024, with a significant number of units projected to be completed by the end of 2024. An additional packaging and labeling CMO is expected to start commercial supply of UDENYCA in the first quarter of 2025.

Management Comments

• Based on the production schedule, a significant number of units are projected to be completed without further interruption or delay by the end of 2024.
• We expect to restock the distribution channels as fast as possible, as we expect to ship final product lots as they are completed, making sure they get to customers in an expedited fashion.

Industry Context

The report highlights the challenges and opportunities in the biosimilar and immuno-oncology markets, including competition, pricing pressures, and regulatory hurdles. The company's focus on commercializing UDENYCA and LOQTORZI, while developing its pipeline, reflects a broader trend in the biopharmaceutical industry.

Comparison to Industry Standards

• Coherus's revenue growth in UDENYCA sales is notable, reflecting a successful launch and market penetration, but the temporary supply interruption highlights the risks associated with reliance on third-party manufacturers, a common challenge in the industry.
• The company's strategic decision to divest its CIMERLI and YUSIMRY franchises to focus on its core oncology business is a common strategy in the biopharmaceutical industry, where companies often prioritize their most promising assets.
• The company's new term loan facility and revenue participation agreement are typical financing strategies for companies in the biopharmaceutical industry, which often require significant capital to fund research and development and commercialization efforts.
• The company's pipeline of immuno-oncology product candidates, including casdozokitug and CHS-114, reflects a broader trend in the industry towards developing novel therapies for cancer.
• The company's reliance on third-party CMOs for manufacturing is a common practice in the industry, but the UDENYCA supply interruption highlights the risks associated with this approach.

Legal Proceedings

• The company is a party to various legal proceedings and claims that arise in the ordinary, routine course of business.
• The company received a demand letter from Zinc Health Services, LLC asserting that Zinc was entitled to approximately $14.0 million from the Company for claims related to certain sales of UDENYCA from October 2020 through December 2021.

Stakeholder Impact

• Shareholders may be concerned about the temporary supply interruption of UDENYCA and its impact on future revenue.
• Employees may be affected by the company's cost containment initiatives and the termination of the TIGIT program.
• Customers may experience a temporary disruption in the supply of UDENYCA.
• Suppliers may be affected by the company's reliance on third-party manufacturers and CMOs.

Next Steps

• The company expects UDENYCA production to resume in early November 2024.
• The company expects an additional packaging and labeling CMO to start commercial supply of UDENYCA in the first quarter of 2025.
• The company plans to initiate a randomized Phase 2 study in HCC evaluating casdozokitug in combination with toripalimab and bevacizumab in the fourth quarter of 2024.

Key Dates

Keywords

UDENYCA, LOQTORZI, biosimilar, immuno-oncology, supply interruption, financial results, asset sales, clinical trials, regulatory approval, manufacturing, debt, revenue